drugset / Trial / NCT00578877
Contraceptive Effectiveness and Safety of the SILCS Diaphragm
Phase 2/3
Completed
450 enrolled
CONRAD
FHI 360 · collabReProtect Inc · collabUnited States Agency for International Development (USAID) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This multi-center contraceptive effectiveness and safety study of the SILCS diaphragm will enroll approximately 450 couples at risk for pregnancy at six study sites in the U.S. The study will randomly assign approximately 300 couples to use the SILCS diaphragm with BufferGel and approximately 150 couples to use the SILCS diaphragm with Gynol II (2% N-9 gel). At two sites, a substudy involving colposcopy and microflora will be conducted in about 80 women (40 at each site). The primary objective of this study is to estimate the cumulative 6-month typical-use pregnancy probability for women using the SILCS diaphragm with a contraceptive gel.
Timeline
- Start
- 2008-01
- Primary completion
- 2009-10
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buffer Gel | Unknown | 5 ml | — |
| Subject | Nonoxynol-9 | Small molecule | 5 ml | — |
Indications
No indication recorded.